Takeda fails to gain FDA approval of diabetes drug alogliptin

04/25/2012 | MedCityNews.com

The FDA issued a complete response letter to Takeda Pharmaceutical for diabetes drug alogliptin as stand-alone treatment and in combination with Actos, another therapy by the drugmaker. Takeda, which licensed alogliptin from Furiex Pharmaceuticals, "will immediately request a meeting with the FDA to determine the appropriate next steps and [is] committed to addressing outstanding issues," said Thomas Harris, vice president of regulatory affairs at Takeda Global Research & Development Center.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA